Source-grounded facts extracted from CytomX Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Charles Fuchs was appointed as Director at CytomX Therapeutics, Inc..
“On July 24, 2026, Charles Fuchs, M.D., M.P.H., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective immediately, as a Class II director”
CytomX Therapeutics, Inc.: Increased authorized shares of common stock from 300,000,000 to 600,000,000 (effective 2026-06-22).
“On June 22, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 300,000,000 to 600,000,000 shares (the “Charter Amendment”).”
CytomX Therapeutics, Inc. shareholders approved Non-binding advisory vote on the frequency of future advisory votes on executive compensation at the 2026-06-17 meeting.
“Proposal 7. The non-binding, advisory vote regarding the frequency of future advisory votes by stockholders on the compensation of the Company’s named executive officers: 1 YEAR 2 YEARS 3 YEARS ABSTAIN BROKER NON-VOTES 145,004,404 1,298,607 2,352,377 349,574 34,599,122”
CytomX Therapeutics, Inc. shareholders approved Non-binding advisory vote on the compensation of the named executive officers (Say-on-Pay) at the 2026-06-17 meeting.
“Proposal 6. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 147,127,715 1,722,679 154,568 34,599,122”
CytomX Therapeutics, Inc. shareholders approved Approval of an amendment to the Amended and Restated Employee Stock Purchase Plan at the 2026-06-17 meeting.
“Proposal 5. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Employee Stock Purchase Plan, as described in the Proxy Statement. FOR AGAINST ABSTAIN BROKER NON-VOTES 147,375,197 1,468,576 161,189 34,599,122”
CytomX Therapeutics, Inc. shareholders approved Approval of an amendment to the 2015 Plan at the 2026-06-17 meeting.
“Proposal 4. The Company’s stockholders approved an amendment to the 2015 Plan, as described in the Proxy Statement. FOR AGAINST ABSTAIN BROKER NON-VOTES 147,079,951 1,745,001 180,010 34,599,122”
CytomX Therapeutics, Inc. shareholders approved Approval of an amendment to the Amended and Restated Certificate of Incorporation to increase authorized shares of common stock from 300,000,000 to 600,000,000 at the 2026-06-17 meeting.
“Proposal 3. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 shares to 600,000,000 shares. FOR AGAINST ABSTAIN 178,362,995 4,771,689 469,400”
CytomX Therapeutics, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm at the 2026-06-17 meeting.
“Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. FOR AGAINST ABSTAIN 182,976,052 382,681 245,351”
CytomX Therapeutics, Inc. shareholders approved Election of Class II director nominees to the Board to hold office until the 2029 Annual Meeting at the 2026-06-17 meeting.
“Proposal 1. The Company’s stockholders elected the Class II director nominees below to the Board to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal. NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Matthew P. Young 146,742,827 2,062,471 199,664 34,599,122 Elaine V. Jones Ph.D. 131,377,301 17,428,951 198,710 34,599,122”
CytomX Therapeutics, Inc. amended Amendment No. 4 with Regeneron Pharmaceuticals, Inc. valued at Total potential target nomination payments and preclinical, clinical, regulatory and commercial mile (effective 2026-05-31).
“On May 29, 2026, the Company and Regeneron entered into Amendment No. 4 to the Agreement (“Amendment No. 4”), effective May 31, 2026”
CytomX Therapeutics, Inc. reported for the quarter ended March 31, 2026 results: revenue 10.3 million.
“Total revenue was $10.3 million for the quarter ended March 31, 2026, compared to $50.9 million for the first quarter of 2025.”
CytomX Therapeutics, Inc. reported the year ended December 31, 2025 results: revenue $76.2 million.
“Total revenue was $76.2 million for the year ended December 31, 2025, compared to $138.1 million in 2024.”
CytomX Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“5 and February 21, 2025 the Company’s common stock, $0.00001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock.”
Jeffrey Landau was terminated as Senior Vice President, Chief Business Officer, and Head of Strategy at CytomX Therapeutics, Inc..
“On January 30, 2025, Jeffrey Landau, Senior Vice President, Chief Business Officer, and Head of Strategy, of CytomX Therapeutics, Inc. (the “Company”) and the Company agreed that Mr. Landau’s employment by the Company would terminate, effective February 7, 2025.”
CytomX Therapeutics, Inc. announced a restructuring with charges of approximately $5 million to $6 million affecting general and administrative functions and staff supporting non-partnered internal research programs (approximately 40%).
“cash runway into the second quarter of 2026. In connection with the restructuring, the Company estimates that it will incur aggregate restructuring charges of approximately $5 million to $6 million, which the Company expects will be substantially recorded in the first quarter of 2025. The estimated restructuring charges are related primarily to one-time”
Chris Ogden was appointed as Chief Financial Officer at CytomX Therapeutics, Inc..
“On June 12, 2024, CytomX Therapeutics, Inc. (the “Company”) appointed Chris Ogden to serve as the Company’s Chief Financial Officer effective June 15, 2024 (the “Effective Date”).”
CytomX Therapeutics, Inc.: Increased authorized shares of common stock from 150,000,000 to 300,000,000 shares (effective 2024-05-17).
“On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).”
CytomX Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.
“Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723”
CytomX Therapeutics, Inc. shareholders approved Amendment to increase authorized shares of common stock from 150,000,000 to 300,000,000 at the 2024-05-15 meeting.
“Proposal 3. The Company’s stockholders approved of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares. FOR AGAINST ABSTAIN 42,707,436 3,211,496 999,741”
CytomX Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2024-05-15 meeting.
“Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. FOR AGAINST ABSTAIN 46,522,474 369,346 26,853”
CytomX Therapeutics, Inc. shareholders approved Election of Class III directors at the 2024-05-15 meeting.
“Proposal 1. The Company’s stockholders elected the Class III director nominees below to the Company’s Board of Directors to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal. NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Alan Ashworth, Ph.D., FRS 28,770,373 514,091 79,486 17,554,723 James R. Meyers 28,970,141 324,310 69,499 17,554,723 Halley Gilbert 24,008,423 5,271,685 83,842 17,554,723”
CytomX Therapeutics, Inc. reported financial results for first quarter 2024.
“On May 8, 2024, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months ended March 31, 2024.”
CytomX Therapeutics, Inc.: Amended and restated bylaws to modernize stockholder nomination and proposal procedures, remove 'acting in concert' provisions, and make clarifying changes (effective 2024-03-20).
“On March 20, 2024, the Board unanimously adopted Amended and Restated Bylaws of the Company (the bylaws, as so amended and restated, the “Amended and Restated Bylaws”), effective immediately, to, among other things, modernize and enhance certain disclosure and procedural requirements related to stockholder nominations of directors and submissions of stockholder proposals regarding other business at stockholder meetings, including removing the “acting in concert” provisions previously contained in the Company’s bylaws, as well as certain other clarifying, technical and conforming changes.”
Zhen Su was appointed as Class I director at CytomX Therapeutics, Inc..
“On March 20, 2024, Zhen Su, M.D., M.B.A., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective March 20, 2024, as a Class I director, with an initial term expiring at the Company’s 2025 annual meeting of stockholders, filling a vacancy.”
CytomX Therapeutics, Inc. reported financial results for the year ended December 31, 2023.
“On March 11, 2024, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2023.”
CytomX Therapeutics, Inc. reported financial results for third quarter 2023.
“On November 7, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three and nine months ended September 30, 2023.”
CytomX Therapeutics, Inc. entered into Transition Agreement with AbbVie Global Enterprises Ltd. valued at royalties low-to-mid single digit percentages; milestones and royalties mid-to-high single digit per (effective 2023-08-22).
“On August 22, 2023, CytomX Therapeutics, Inc. (the “Company”) entered into a Transition Agreement (the “Transition Agreement”) with AbbVie Global Enterprises Ltd. (“AbbVie”), pursuant to which the Company regained exclusive worldwide rights to develop CX-2029, a CD71-targeting conditionally activated antibody drug conjugate.”
CytomX Therapeutics, Inc. reported financial results for second quarter 2023.
“On August 8, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three and six months ended June 30, 2023.”
CytomX Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $30.0 million (effective 2023-06-29).
“On June 29, 2023, CytomX Therapeutics, Inc. (the “Company”) entered into a unit purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”).”
CytomX Therapeutics, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-14 meeting.
“Proposal 3. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 22,139,070 1,486,286 938,849 19,348,475”
CytomX Therapeutics, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
“Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. FOR AGAINST ABSTAIN 43,291,956 562,880 57,844 As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.”
CytomX Therapeutics, Inc. shareholders approved Election of Class II directors at the 2023-06-14 meeting.
“Proposal 1. The Company’s stockholders elected the Class II director nominees below to the Company’s Board of Directors to hold office until the 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal. NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Matthew P. Young 23,793,074 732,946 38,185 19,348,478 Elaine V. Jones, Ph.D. 18,414,845 6,111,386 37,974 19,348,478”
CytomX Therapeutics, Inc. reported financial results for the three months ended March 31, 2023.
“On May 9, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months ended March 31, 2023.”
CytomX Therapeutics, Inc. reported financial results for the year ended December 31, 2022.
“On March 27, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.”
CytomX Therapeutics, Inc. reported that prior financial statements should not be relied upon.
“determined that the Company's financial statements and related earnings press releases for the years ended December 31, 2018, 2019, 2020 and 2021, and each of the previously reported quarters from 2018 through 2022 (the “Restated Periods”), should no longer be relied upon.”
CytomX Therapeutics, Inc. entered into Collaboration and License Agreement with ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc. valued at $35 million (effective 2022-12-30).
“On December 30, 2022, CytomX Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc. (“Moderna”),”
CytomX Therapeutics, Inc. entered into Collaboration and License Agreement with Regeneron Pharmaceuticals Inc. valued at $30 million (effective 2022-11-16).
“On November 16, 2022, CytomX Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with Regeneron Pharmaceuticals Inc. (“Regeneron”), pursuant to which the Company and Regeneron will collaborate on the creation of conditionally-activated investigational bispecific cancer therapies utilizing the Company’s Probody ® therapeutic platform and Regeneron’s Veloci-Bi ® bispecific antibody development platform.”
CytomX Therapeutics, Inc. reported financial results for for the three months and nine months ended September 30, 2022.
“On November 8, 2022, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months and nine months ended September 30, 2022.”
Chris Ogden was appointed as Principal Financial Officer and Principal Accounting Officer at CytomX Therapeutics, Inc..
“designated Chris Ogden, the Company's Senior Vice President, Finance and Accounting, to assume the responsibilities of principal financial officer and principal accounting officer, effective immediately”
Carlos Campoy departed as SVP, Chief Financial Officer at CytomX Therapeutics, Inc..
“the planned departure of Carlos Campoy, the Company's SVP, Chief Financial Officer and former principal financial officer and principal accounting officer, whose employment is expected to terminate effective as of September 30, 2022.”
Alison Hannah was terminated as SVP, Chief Medical Officer at CytomX Therapeutics, Inc..
“the employment of Carlos Campoy, the Company’s SVP, Chief Financial Officer, and Alison Hannah, M.D., the Company’s SVP, Chief Medical Officer, is expected to terminate effective as of September 30, 2022”
Carlos Campoy was terminated as SVP, Chief Financial Officer at CytomX Therapeutics, Inc..
“the employment of Carlos Campoy, the Company’s SVP, Chief Financial Officer, and Alison Hannah, M.D., the Company’s SVP, Chief Medical Officer, is expected to terminate effective as of September 30, 2022”
Amy Peterson was terminated as President and Chief Operating Officer at CytomX Therapeutics, Inc..
“the employment of Amy Peterson, M.D., the Company’s President and Chief Operating Officer, is expected to terminate effective September 12, 2022”
John A. Scarlett retired as Director at CytomX Therapeutics, Inc..
“On April 11, 2022, John A. Scarlett, M.D. informed CytomX Therapeutics, Inc. (the “Company”) of his retirement from the Company’s board of directors, effective when his current term expires at the Company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022.”
Frederick W. Gluck retired as director at CytomX Therapeutics, Inc..
“On March 23, 2022, CytomX Therapeutics, Inc. (the “Company”) announced the retirement of Frederick W. Gluck from the Company’s board of directors, effective as of June 30, 2022.”
Chris Ogden was appointed as interim principal accounting officer at CytomX Therapeutics, Inc..
“In connection with Mr. Campoy’s personal leave of absence, the Company’s Board of Directors designated Chris Ogden, the Company’s Vice President, Finance and Accounting, to assume the responsibilities of interim principal accounting officer, effective February 14, 2022.”
Sean McCarthy changed role as Chairman and Chief Executive Officer at CytomX Therapeutics, Inc..
“Dr. Sean McCarthy will continue in his positions as Chairman and Chief Executive Officer of the Company, while Dr. Peterson assumes the title of President previously held by Dr. McCarthy.”
Amy Peterson changed role as President and Chief Operating Officer at CytomX Therapeutics, Inc..
“On February 2, 2022, the Board of Directors of CytomX Therapeutics, Inc. (the “Company”) promoted Dr. Amy Peterson to serve as President and Chief Operating Officer of the Company.”
Alan Ashworth was appointed as Class III director at CytomX Therapeutics, Inc..
“On September 29, 2021, Alan Ashworth, Ph.D., FRS was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective September 29, 2021, as a Class III director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling a vacancy.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.